Sanders Morris Harris LLC Buys 34,034 Shares of uniQure (NASDAQ:QURE)

Sanders Morris Harris LLC raised its stake in uniQure (NASDAQ:QURE) by 50.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,104 shares of the biotechnology company’s stock after purchasing an additional 34,034 shares during the period. Sanders Morris Harris LLC owned approximately 0.21% of uniQure worth $1,803,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. abrdn plc boosted its holdings in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. bought a new stake in uniQure in the 3rd quarter valued at $7,360,000. Point72 Asset Management L.P. boosted its holdings in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the period. Privium Fund Management B.V. lifted its holdings in shares of uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after acquiring an additional 6,362 shares during the period. 78.83% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.74% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on QURE shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, December 10th. Stifel Nicolaus raised their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Finally, The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Trading Up 0.3 %

Shares of NASDAQ:QURE traded up $0.04 during trading on Thursday, hitting $14.03. 37,041 shares of the company’s stock were exchanged, compared to its average volume of 1,339,829. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The firm has a 50-day moving average price of $11.83 and a two-hundred day moving average price of $8.24. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $683.86 million, a P/E ratio of -2.83 and a beta of 0.41.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. Equities analysts predict that uniQure will post -3.74 earnings per share for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.